Insider filing · RARE
Emil D Kakkis
President & CEO
profile →
Ultragenyx Pharmaceutical Inc.
RARE · Healthcare · 27 filings in 24 months
ticker →
Emil D Kakkis sold $1.2M of Ultragenyx Pharmaceutical (RARE)
Executed Mar 2, disclosed Mar 3, 1 day later.
Value, as filed
$1.2M
54,404 sh × $22.80
Executed
Mar 2
the trade date, as filed
Disclosed
Mar 3
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
EKEmil D Kakkis (President & CEO) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Ultragenyx Pharmaceutical Inc. (RARE). The largest single filing was $1.2M of RARE (54,404 sh × $22.80, as filed), executed Mar 2.
The name
RAREHealthcare · Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Emil D Kakkis in RARE
RARESALE
Ultragenyx Pharmaceutical Inc.
$4.2M98,434 sh across 2 lots
Exec Feb 28 2025
Filed Mar 4 2025 · 5:30 PM ET RARESALE Ultragenyx Pharmaceutical Inc. $495K
11,727 sh × $42.23
Exec Dec 30 2024
Filed Dec 31 2024 · 5:30 PM ET RARESALE Ultragenyx Pharmaceutical Inc. $414K
8,273 sh × $50.00
Exec Dec 10 2024
Filed Dec 11 2024 · 5:30 PM ET